CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

A research team affiliated with UNIST has unveiled an innovative technology to eliminate drug-resistant cancer cells using ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Becky Kamowitz was appointed executive director of The Skin Cancer Foundation in January 2025. She talks about the ...

Medicare covers inpatient and outpatient care for skin cancer. People with Original Medicare parts A and B or Medicare Advantage plans can expect extensive coverage, but they will likely have out ...

Although long considered a disease of aging, certain cancers are turning up more often in younger women, according to a new report. By Roni Caryn Rabin More Americans are surviving cancer ...

This positive news in skin cancer is notable for several reasons: LIBTAYO gained FDA approval in 2018 for CSCC and has also been approved to treat non-small cell lung cancer (NSCLC) as well.

“Regeneron has long been a pioneer in non-melanoma skin cancer research. Libtayo was the first PD-1 inhibitor approved for certain patients with advanced cutaneous squamous cell carcinoma and has ...

SHOCKING figures lay bare how almost 60 per cent of people diagnosed with the six least survivable cancers die from their disease within a year. Over 90,000 people in the UK are diagnosed with one ...

Add articles to your saved list and come back to them any time. A bayside suburb has earned the undesirable title of Melbourne’s skin cancer hotspot, according to an analysis of a decade of data.